My inclination would be to avoid administering an anthracycline to such a patient, as long as you include a taxane and carboplatin in her treatment regimen. If you're treating her in the neoadjuvant setting, Sharma and colleagues achieved a similar pCR rate with every 3-week docetaxel and carboplati...

After weighing the risks and benefits, I might. An 80-year-old patient has a life expectancy of about 7 years and the risk of relapse for a TNBC is highest in the first couple of years, so this patient is at risk for relapse and death from the breast cancer.In the ABC trials, for TNBC involving node...

Treatment of breast cancer in the elderly is such an important and complicated question. A healthy woman in her early 80s has an actuarial survival of 8-10 years, so it cannot be assumed that she will die of other causes before developing metastatic breast cancer. On the other hand, patients in thei...